By ipomarket.in Editorial Team · Last reviewed: 2026-09-18
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
Before a company opens its IPO, you may notice news items with headlines like "Company X schedules plant visit and analyst meet." These are not casual site tours. They are structured, regulated events where analysts and institutional investors get a first-hand look at a company's operations and management. For retail investors, understanding what happens at these meetings — and their limits — helps you read IPO coverage more critically.
This article explains what plant visits and analyst meets are, where they sit in the IPO timeline, what SEBI rules require, and why the sentiment they generate should be treated as one input, not a verdict.
What is a plant visit and an analyst meet?
A plant visit is exactly what it sounds like: analysts, fund managers, and institutional investors are invited to a company's manufacturing facility or operating site to observe operations, capacity, and processes in person. An analyst meet is a session where the company's senior management presents the business to analysts and investors and answers questions.
For a listed company, these events are conducted under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Companies typically state that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions, and that discussions are limited to publicly available information. Companies also file intimations of such meetings with the NSE and BSE and put the schedule on their websites.
One clarification matters for IPO watchers: the Regulation 30(6) framework applies to already-listed companies. In the context of a company preparing to go public, the equivalent activity is usually the IPO roadshow, which serves a similar purpose — showcasing the business to analysts and institutions before pricing.
Where these events sit in the IPO timeline
Roadshows, which can include site visits and management presentations, generally happen after a company has appointed its merchant bankers, prepared its offer documents, and filed a draft offer document. If you want to understand what that draft document contains, see our guide on what is a DRHP and how to read it.
According to industry descriptions, the IPO roadshow process in India typically runs over two to four weeks and can include meetings with anchor investors, domestic institutions, international investors, and, in some formats, retail-facing sessions. During these meetings, company leadership — often the CMD or CEO, the CFO, and sometimes independent directors — walks investors through the business model, financials, industry opportunity, risk factors, and the intended use of IPO proceeds.
Separately, the book running lead managers (BRLMs) must file a due diligence certificate with SEBI confirming that appropriate due diligence has been undertaken on the issuer. Under Schedule V of the SEBI ICDR Regulations, the lead manager certifies that disclosures in the offer document are true and complete.
Why companies hold them
The practical purpose is to build interest and gauge demand before the price is finalised. The company and its underwriters set the final offer price by weighing investor response and prevailing market conditions. In other words, the feedback gathered from analysts and institutions during roadshows and meetings feeds directly into how the price band is set and how demand is estimated.
This is a marketing exercise as much as an informational one. That framing is important: the goal of a roadshow is to generate interest, not to provide a neutral audit of the company.
What the research suggests about analyst coverage
There is some academic work on how analyst participation relates to IPO outcomes, and it is worth reading carefully rather than at face value.
One study of 157 IPOs issued in India during 2007–2012 found that analyst recommendations were associated with reduced underpricing, and that favourable recommendations from more participating analysts were linked to higher investor confidence and a greater probability of oversubscription. This is a dated dataset (2007–2012), and market dynamics have changed considerably since then, so treat it as historical context rather than a rule for 2026.
Separately, a January 2026 research paper on the Chinese IPO market found that pre-IPO analyst optimism was positively related to offer price revisions and first-day returns, and that analysts connected to the underwriter were more likely to cover an IPO and issue more optimistic forecasts. This raises a fair question about potential bias, but it is drawn from a different regulatory environment. Whether it applies to Indian IPOs is unconfirmed.
The honest position: there is no current Indian research (2025–2026) we could find that quantifies how plant visit disclosures or analyst sentiment influence retail investor outcomes, underpricing, or grey market premium.
What this means for retail investors
Here is the core takeaway. Plant visits and analyst meets give institutions and analysts on-ground operational context that a retail investor reading the prospectus at home simply does not have. That is an information gap, and it is worth being aware of.
But a few points cut against over-weighting analyst sentiment:
- SEBI does not endorse any IPO. SEBI is explicit that it does not recommend any issue and that investors should make their own decision based on the offer document disclosures.
- Discussions are meant to stay public. Companies commit that no UPSI is shared at these meetings, so in principle the substance should also be available in the offer document you can read.
- Some analysts have affiliations. Analysts attending these events may be connected to the underwriter or have institutional relationships, which can shape tone. This is worth keeping in mind whenever you read a glowing pre-IPO note.
If you are comparing what analysts say against the actual filing, our guides on how to read broker and influencer IPO recommendations critically and how to analyse IPO financials from the RHP are more useful anchors than post-meeting headlines.
It is also worth separating operational insight from grey market chatter. A plant visit does not set the grey market premium; GMP is an unofficial, unregulated indicator driven by sentiment and supply-demand in an informal market. Whether plant visit findings influence final GMP or subscription levels is not something we could verify with data.
A practical way to use the coverage
Rather than treating a plant visit report as a signal to act, use it as a prompt to check specifics in the offer document: stated capacity, utilisation rates, customer concentration, and the actual use of proceeds. If an analyst is impressed by "scale," confirm what the RHP says about revenue per unit, margins, and debt. The meeting is where a story is told; the DRHP or RHP is where you verify it.
FAQ
Can retail investors attend plant visits or analyst meets before an IPO?
In most cases these events are aimed at analysts, fund managers, and institutional investors. Whether and how retail investors can participate, or access recorded disclosures from such meetings, is not clearly established for pre-IPO roadshows. For listed companies, intimations of analyst meets are filed with the exchanges and posted on company websites, so the schedule is public even if the meeting itself is not open to everyone.
Is any secret information shared during a plant visit?
Companies typically state that no Unpublished Price Sensitive Information is shared and that discussions are limited to publicly available information. In principle, the substance discussed should also be traceable in the offer document. We could not independently verify how consistently this holds in every case.
Does a plant visit affect the IPO price or subscription?
Roadshows and management meetings feed into how underwriters gauge demand and set the final price. However, we found no current Indian data quantifying the specific impact of plant visits on subscription levels, underpricing, or GMP. Treat any such claim as unverified.
Should I rely on analyst opinions formed after a plant visit?
Analyst views are one input, not a recommendation to act. SEBI does not endorse any IPO and advises investors to decide based on offer document disclosures. Some analysts may have underwriter or institutional affiliations, so read their notes alongside the filing rather than in place of it.
Bottom line
Plant visits and analyst meets are legitimate, regulated parts of how companies present themselves before going public. They give institutions on-ground insight that retail investors usually lack. But the sentiment they generate is a marketing output shaped partly by relationships and incentives — not an independent verdict on the company. The offer document, read carefully, remains your most reliable source.
Last reviewed: 2026-09-18 by the ipomarket.in Editorial Team.